



Bronchiolitis




ΣΑ Παπίρης
Καθηγητής Ιατρικής
Διευθυντής Β' Πνευμονολογικής Κλινικής
Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών
«Αττικών» Πανεπιστημιακό Νοσοκομείο

BRONCHIOLITIS


is the **inflammation of the bronchiolar wall** which is either the **prominent** histopathologic feature and **characterizes a distinct clinical entity (rare),**


or **participates** in the inflammation of the **airways and/or surrounding alveolar structures** in **several already defined clinical entities (common)**


Bronchiolitis



BRONCHIOLITIS









The secondary pulmonary lobule is a fundamental unit of lung structure, and it reproduces the lung in miniature.

Airways, pulmonary arteries, veins, lymphatics, and the lung interstitium are all represented at the level of the secondary lobule.

acinar artery and bronchioles
diameter 0.5 mm

bronchiole wall thickness 0.05-0.1 mm






**Interlobular septa and
septal structures**

Centrilobular structures

Lobular parenchyma



Thin-Section CT Diagnosis of Lobular Abnormalities

Pathologic alternations in secondary lobular anatomy visible on thin-section CT scans may be described as:

Perilobular (interlobular septal thickening and peripheral lobular diseases),
Centrilobular, and
Panlobular.



Perilobular Pattern: Differential Diagnosis

CT Finding

Differential Diagnosis

Smooth interlobular septal thickening

Pulmonary edema, hemorrhage, or veno-occlusive disease; lymphangitic spread of neoplasm; lymphangiomatosis; amyloidosis; pneumonia; alveolar proteinosis

Nodular interlobular septal thickening

Lymphangitic spread of neoplasm, lymphoproliferative disease (eg, lymphocytic interstitial pneumonia), sarcoidosis, silicosis and coal worker's pneumoconiosis, amyloidosis


Irregular interlobular septal thickening

End-stage lung disease, sarcoidosis, usual interstitial pneumonia, asbestosis, hypersensitivity pneumonitis


Peripheral lobular abnormalities

Idiopathic pulmonary fibrosis, usual interstitial pneumonia, organizing pneumonia







a.



b.

Perilobular







Centrilobular Nodules: Differential Diagnosis



| Cause | Differential Diagnosis |
|-------------------------------|--|
| Bronchiolar infection | Endobronchial spread of tuberculosis, nontuberculous mycobacteria or other granulomatous infection, bronchopneumonia, infectious bronchiolitis, cystic fibrosis |
| Bronchiolar inflammation | Hypersensitivity pneumonitis, diffuse panbronchiolitis, asthma, allergic bronchopulmonary aspergillosis, Langerhans cell histiocytosis, organizing pneumonia, bronchiolitis obliterans, respiratory bronchiolitis in smokers, asbestosis, follicular bronchiolitis |
| Endobronchial spread of tumor | For example, bronchioloalveolar carcinoma |
| Angiocentric disease | Pulmonary edema, pulmonary vasculitis, talcosis, pulmonary hemorrhage or hemosiderosis, metastatic calcification, pulmonary hypertension |
| Perilymphatic disease | Sarcoidosis, silicosis and coal worker's pneumoconiosis, lymphangitic spread of neoplasm, lymphocytic interstitial pneumonia |

Centrilobular



Disease that primarily affects **centrilobular bronchioles** and results in **inflammation, infiltration,** or fibrosis of the surrounding interstitium and alveoli





Nodular opacities



“Tree in bud”



Centrilobular low attenuation





Panlobular


Table 3


Panlobular Nodules: Differential Diagnosis






| CT Finding | Differential Diagnosis |
|------------------------------|--|
| Lobular consolidation | Bronchopneumonia, organizing pneumonia, eosinophilic pneumonia, bronchioloalveolar carcinoma |
| Lobular ground-glass opacity | Bronchopneumonia, viral infection, <i>Pneumocystis carinii</i> pneumonia, <i>Mycoplasma pneumoniae</i> , pulmonary edema, hypersensitivity pneumonitis, alveolar proteinosis, lipid pneumonia |
| Lobular low attenuation | Mosaic perfusion due to airways or vascular disease, emphysema (panlobular or paraseptal) |
| Headcheese sign | Hypersensitivity pneumonitis, desquamative interstitial pneumonia, respiratory bronchiolitis–interstitial lung disease, sarcoidosis, atypical infections with bronchiolitis (eg, <i>M pneumoniae</i>) |



b.










a.


Bronchiolitis





Hypersensitivity Disorders

- **Bronchial Asthma**
- **ABPA (ABPM)**
- **Bronchocentric granulomatosis**
- **Hypersensitivity Pneumonitis**
- **Chronic eosinophilic pneumonia**
- **Churg-Strauss vasculitis**













The patient was advised to be treated with corticosteroids per os but was not compliant to his treatment




Post surgery




On admission














The patient was treated with mycophenolate mofetil and low dose of prednisone with significant response to tx





Bronchiolitis



SMOKING

- Chronic Bronchitis Bronchiolitis
- Centrilobular emphysema
- Panlobular emphysema
- RB-ILD
- Langerhan's cells granulomatosis H-x

The NEW ENGLAND
JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

OCTOBER 27, 2011

VOL. 365 NO. 17

Small-Airway Obstruction and Emphysema in Chronic
Obstructive Pulmonary Disease



John E. McDonough, M.Sc., Ren Yuan, M.D., Ph.D., Masaru Suzuki, M.D., Ph.D., Nazgol Seyednejad, B.Sc.,
W. Mark Elliott, Ph.D., Pablo G. Sanchez, M.D., Alexander C. Wright, Ph.D., Warren B. Gelfer, M.D.,
Leslie Litzky, M.D., Harvey O. Coxson, Ph.D., Peter D. Paré, M.D., Don D. Sin, M.D., Richard A. Pierce, Ph.D.,
Jason C. Woods, Ph.D., Annette M. McWilliams, M.D., John R. Mayo, M.D., Stephen C. Lam, M.D.,
Joel D. Cooper, M.D., and James C. Hogg, M.D., Ph.D.


The micro CT results extend earlier reports by showing that there is both **widespread narrowing and loss of smaller conducting airways** before the onset of emphysematous destruction in both **centrilobular and panlobular** emphysema phenotypes of COPD.

This process readily explains the observed increase by a factor of 4 to 40 in small-airway resistance in patients with COPD


RB-ILD / DIP

RB occurs as an incidental finding in smokers, so it is impossible to know whether it is the main problem or there is some other lesion not been sampled





A surgical lung biopsy is required to make a confident diagnosis of RB-ILD and associated DIP.









CASE FOR DIAGNOSIS

Dry cough and dyspnoea rapidly increasing to respiratory failure in a male smoker

I. Sigala*, **I. Kalomenidis***, **K. Malagari[#]**, **D. Rontogianni[†]**, **G. Kapotsis***, **T. Vassilakopoulos***,
C. Roussos* and **S.A. Papiris***



Bronchiolitis



Toxic Exposures Associated with Bronchiolitis, with or without Obliterans

Nitrogen dioxide (“nitrous fume”)*

Spillage of nitric acid (component of jet and missile fuels)

Metal pickling

Silo gas

Chemical manufacturing (explosives, dyes, lacquers, celluloid)

Detonation of explosives

Electric arc or acetylene gas welding

Contamination of anesthetic gases (nitrous oxide gas cylinder)

Nitrocellulose combustion

Tobacco smoke

Fire smoke (firemen, astronauts, others exposed to burning materials)*,†

Sulfur dioxide†

Burning of sulfur-containing fossil fuels

Bleaching of wool, straw, wood pulp

Sugar refining, fruit preserving

Fungicides

Refrigerants

Ore smelting

Acid production

Ammonia†

Fertilizer and explosives, production, refrigeration

Chlorine⁺

Bleaching, disinfectant and plastic making

Phosgene*

Chemical industry, dye and insecticide manufacturing

Chloropicrin

Trichlorethylene

Ozone

Arc welding and air, sewage, and water treatment

Cadmium oxide

Ore smelting, alloying, and welding

Methyl sulfate

Hydrogen sulfide

Natural gas retrieval, paper pulp, sewage treatment,
tannery work

Hydrogen fluoride

Etching, petroleum industry, silk working

Talcum powder (hydrous magnesium silicate)

Stearate of zinc powder

Oxygen toxicity

Asbestos (chrysotile and amphibole)

Iron oxide[§]

Aluminum oxide[§]

Silica[§]

Sheet silicates (talc, mica, etc.)[§]

Coal[§]

Activated charcoal

Talc

Free-base cocaine*

Chemical weapons (mustard gas and the nerve gases,
sarin, VX, and tabun)[†]




ORIGINAL ARTICLE

Constrictive Bronchiolitis in Soldiers Returning from Iraq and Afghanistan


Matthew S. King, M.D., Rosana Eisenberg, M.D., John H. Newman, M.D.,
James J. Tolle, M.D., Frank E. Harrell, Jr., Ph.D., Hui Nian, Ph.D.,
Mathew Ninan, M.D., Eric S. Lambright, M.D., James R. Sheller, M.D.,
Joyce E. Johnson, M.D., and Robert F. Miller, M.D.


Table 3. Pathological Features of Biopsy Samples Obtained from 38 Soldiers with Constrictive Bronchiolitis.

| Variable | No. of Patients |
|--|-----------------|
| Bronchiolar luminal constriction* | 38 |
| Predominant constrictive stroma | |
| Smooth muscle | 7 |
| Fibrous tissue | 1 |
| Mixed | 28 |
| Pigment deposition | 37 |
| Polarizable material within pigment | 36 |
| Peribronchiolar inflammation | 34 |
| Hypertensive-type arterial change | 28 |
| Respiratory bronchiolitis | 27 |
| Prominent bronchial-associated lymphoid tissue | 19 |
| Mucus plugging | 13 |
| Eosinophils in bronchiolar wall | 7 |
| Luminal granulation | 2 |
| Obliteration of bronchioles | 0 |



Bronchiolitis






14-Nov-2011
11:15:40.73
602 INA 36
MPR THICK


Spin: -0
Tilt: -90

10cm



Bronchiolitis






Acute Bronchiolitis

- **Acute bronchiolitis is a term most often used to describe an illness in infants and children characterized by acute wheezing with concomitant signs of respiratory viral infection**
- **Acute bronchiolitis is the most common disease of the respiratory tract during the first year of life and occurs in annual epidemics during winter**

TABLE 1. Most Common Human Respiratory Viruses and Associated Syndromes

| | Serotypes | Envelope | Nucleic Acid | Illness |
|---------------|------------|----------|--------------|--|
| Adenovirus | 1–49 | No | dsDNA | Pneumonia, acute respiratory distress |
| Coronavirus | 229E, OC43 | Yes | (+) ssRNA | Common cold |
| Influenza | A, B, C | Yes | (-) ssRNA | Pneumonia |
| Parainfluenza | 1–4 | Yes | (-) ssRNA | Croup/bronchitis bronchiolitis (PIV-3) |
| RSV | A, B | Yes | (-) ssRNA | Bronchiolitis, pneumonia |
| Rhinovirus | 100+ | No | (+) ssRNA | Common cold |

dsRNA, double stranded RNA; ssRNA, single stranded RNA; PIV, parainfluenza virus.




Normal lung

A

“patients with suppurative phlegm”
Renè Thèophile Hyacinhe Laënnec

19th century



Bronchiectasis

B

“Uncommon” disease...
architectural derangement...
permanent dilatation of small and larger bronchi...

TABLE 1. CONDITIONS ASSOCIATED WITH BRONCHIECTASIS.

Postinfectious conditions

- Bacteria (pseudomonas, haemophilus)
- Mycobacterium tuberculosis
- Aspergillus species
- Virus (adenovirus, measles virus, influenzavirus, human immunodeficiency virus)

Congenital conditions

- Primary ciliary dyskinesia
- Alpha₁-antitrypsin deficiency
- Cystic fibrosis
- Tracheobronchomegaly (Mounier–Kuhn syndrome)
- Cartilage deficiency (Williams–Campbell syndrome)
- Pulmonary sequestration
- Marfan's syndrome

Immunodeficiency

- Primary
 - Hypogammaglobulinemia
- Secondary
 - Caused by cancer (chronic lymphatic leukemia), chemotherapy, or immune modulation (after transplantation)

Sequelae of toxic inhalation or aspiration

- Chlorine
- Overdose (heroin)
- Foreign body


Rheumatic conditions

- Rheumatoid arthritis
- Systemic lupus erythematosus
- Sjögren's syndrome
- Relapsing polychondritis

Other

- Inflammatory bowel disease (chronic ulcerative colitis or Crohn's disease)
- Young's syndrome (secondary ciliary dyskinesia)
- Yellow nail syndrome (yellow nails and lymphedema)

Bronchiolitis



DRUGS

- Penicillamine
- Hexamethonium
- L-Tryptophan
- Busulfan
- Gold
- Cephalosporin
- Sulfasalazine
- Amiodarone
- Acebutolol
- Sulindac
- Paraquat poisoning
- *Sauropus Androgynus*


Bronchiolitis Obliterans

Sauropus androgynus

- Leafy vegetable in India, Indonesia, China
- Juice mixture with pineapples or guavas
- Consumed for body weight reduction and blood pressure control
- Severe airflow obstruction, $FEV_1 < 1.0$ liter
- Insp/exp HR chest CT correlates with airflow obstruction



Chang AJSPath;21:35-42, 1997&Yang AJR 168:1045-50,1997



Eur Respir J, 1996, 9, 1317–1319
DOI: 10.1183/09031936.96.09061317
Printed in UK - all rights reserved

Copyright ©ERS Journals Ltd 1996
European Respiratory Journal
ISSN 0903 - 1936

CASE STUDY


**Bronchiolitis obliterans in a patient with localized
scleroderma treated with D-penicillamine**


A. Boehler*, P. Vogt**, R. Speich*, W. Weder+, E.W. Russi*

Amiodarone


Review of Pulmonary Effects and Toxicity

Spyros A. Papiris, Christina Triantafyllidou, Likurgos Kolilekas, Despoina Markoulaki and Effrosyni D. Manali





Bronchiolitis



Eur Respir J 2006; 28: 862–871
DOI: 10.1183/09031936.06.00131805
Copyright ©ERS Journals Ltd 2006

SERIES “RARE INTERSTITIAL LUNG DISEASES”
Edited by C. Vogelmeier and U. Costabel
Number 4 in this Series




Diffuse panbronchiolitis

V. Poletti*[#], G. Casoni*, M. Chilosi[†] and M. Zompatori⁺

Diffuse panbronchiolitis is an idiopathic inflammatory disease, well recognised in Japan and principally affecting the respiratory bronchioles, causing a progressive suppurative and severe obstructive respiratory disorder. If left untreated, DPB progresses to bronchiectasis, respiratory failure and death.

Diffuse Panbronchiolitis

- **“Diffuse”** refers to the distribution of the lesions **throughout both lungs**, and **“pan-”** refers to the involvement of inflammation in **all layers of the respiratory bronchioles**
- **rare form of bronchiolitis and chronic sinusitis**
- **Few cases occurring in non-Asian patients** have been described .
- **HLA Bw54**









TABLE 2 Diagnostic criteria for diffuse panbronchiolitis


1. Persistent cough, sputum and exertional dyspnoea
2. History of chronic paranasal sinusitis
3. Bilateral diffuse small nodular shadows on a plain chest radiography film or centrilobular micronodules on chest computed tomography images
4. Coarse crackles
5. FEV₁/FVC <70% and P_aO₂ <80 mmHg
6. Titre of cold haemagglutinin ≥64

Type I




overinflation

II




overinflation
+
bilateral nodular shadows without exceeding one lung

III




overinflation
+
bilateral nodular shadows all over lung

IV




overinflation
+
tram line or small ring shadows

V



overinflation
+
cystic shadows

FIG. 2. Radiographic classification of diffuse panbronchiolitis.








TABLE 1—Structural Differences in Macrolides

| Structure of ring | Name |
|-------------------|---|
| 14-membered | Erythromycin, roxithromycin, clarithromycin, and troleandomycin |
| 15-membered | Azithromycin |
| 16-membered | Spiramycin, josamycin, and midecamycin |

Diffuse panbronchiolitis – effects of macrolides on survival

Survival Rate






Figure 1. Role of neutrophil accumulation in chronic inflammation of airway disease. Chronic inflammation of the airways is characterized by airway epithelial damage, goblet cell hyperplasia, and mucociliary dysfunction. The increased airway mucus layer may cause mucociliary dysfunction and recurrent airway infection. Chronic inflammation is mediated by cytokines, chemokines, oxygen radicals, and chemical mediators, all of which are targets of macrolide therapy. EM = erythromycin; ICAM-1 = intercellular cell adhesion molecule-1; IL = interleukin; LTB₄ = leukotriene B₄; Mac-1 = neutrophil adhesion molecule Mac-1.

TABLE 3 Clinical guidelines for diffuse panbronchiolitis therapy[#]

Macrolides should be applied soon after the diagnosis is made, as there is a better clinical response in the earlier stage

First choice: erythromycin 400 or 600 mg orally

When it is no longer effective or if administration should be stopped because of adverse effects or drug interactions

Second choice: clarithromycin 200 or 400 mg orally or roxithromycin 150 or 300 mg orally[†]

Assessment of response and duration of treatment


Although clinical response can usually be noted within 2-3 months, the treatment should be continued for ≥ 6 months, after which time the overall response should be assessed

Treatment should be completed after a period of 2 yrs when clinical manifestations, radiological findings and pulmonary function measurements have improved and stabilised and without any significant impairment of daily activity

Treatment should be resumed if symptoms reappear after the cessation

In cases of an effective cure in advanced cases with extensive bronchiectasis or respiratory failure, treatment should be continued for >2 yrs


Bronchiolitis





Autoimmune Rheumatic Disorders

- Rheumatoid Arthritis
- Sjögren's syndrome
- SLE
- Polymyositis Dermatomyositis



Bronchiolitis Obliterans





Bronchiolitis Obliterans



BALT → → LIP





Extranodal marginal zone B-cell lymphoma of the lung in Sjögren's syndrome patients: Reappraisal of clinical, radiological, and pathology findings

Spyros A. Papiris^{a,*}, Ioannis Kalomenidis^b, Katerina Malagari^c,
George E. Kapotsis^b, Nikolaos Harhalakis^d, Effrosyni D. Manali^e,
Dimitra Rontogianni^f, Charis Roussos^b, Haralampos M. Moutsopoulos^g

BALT lymphoma

B-cell lymphoma in Sjögren's syndrome

89




Figure 4 Histopathology of MALT-type pulmonary lymphoma. (A) A dense lymphoid infiltrate affects the pulmonary parenchyma and focally invades the alveolar septa. Both, nodular confluent and interstitial infiltration patterns of development (H&E, $\times 100$). (B) Angiocentric (perivascular) and diffuse alveolar infiltration patterns of development of the lymphomatoid cells (H&E, $\times 200$). (C) Bronchocentric (peribronchiolar) infiltration pattern of development of the lymphomatoid cells (H&E, $\times 200$).

9/2/1949, 061Y
St. CT20110120144824
Se. 6
Im. 326

ID: 674714
20/1/2011
15:00:29
HFS




9/2/1949, 061Y
St. CT20110120144824
Se. 6
Im. 249


ID: 674714
20/1/2011
15:00:29
HFS




9/2/1949, 061Y
St. CT20110120144824
Se. 6
Im. 278

ID: 674714
20/1/2011
15:00:29
HFS





Follicular bronchiolitis
1.Αιματοξυλίνη-ηωσίνη (1)
Dr. Demetra Rontogianni
Department of Pathology
Evangelismos Hospital
45 Ipsilantou Street
Athens 10676
Greece



Follicular bronchiolitis

1.Αιματοξυλίνη-ηωσίνη (1)

Dr. Demetra Rontogianni


Department of Pathology

Evangelismos Hospital


45 Ipsilantou Street

Athens 10676

Greece



**Ανοσοιστοχημική χρώση με το
αντίσωμα έναντι του αντιγόνου
CD20(B λεμφοκύτταρα με
βλαστικό κέντρο)
Dr. Demetra Rontogianni
Department of Pathology
Evangelismos Hospital
45 Ipsilantou Street
Athens 10676
Greece**



**Συνοδά CD3+ Τ λεμφοκύτταρα
Ανοσοιστοχημική χρώση με το
αντίσωμα έναντι του CD3 αντιγόνου
Dr. Demetra Rontogianni
Department of Pathology
Evangelismos Hospital
45 Ipsilantou Street
Athens 10676
Greece**



**Δενδριτικά κύτταρα
βλαστικού κέντρου
λεμφοζιδίου.
Ανοσοϊστοχημική χρώση
με το αντίσωμα έναντι του
αντιγόνου CD23 των
δενδριτικών κυττάρων
του βλαστικού κέντρου
του λεμφοζιδίου.
Dr. Demetra Rontogianni
Department of Pathology
Evangelismos Hospital**





FIG. 14. Cellular distribution in hyperplastic bronchus-associated lymphoid tissue. *LE*, lymphoepithelium; *DA*, dome area; *FA*, follicular area (B cell zone); *PFA*, para-follicular area (T cell zone); open circles, IgG; crosses, IgA; closed circles, IgM; closed triangles, CD8; open triangles, CD4; double circles, CD57.

Bronchiolitis



Official publication of the American College of Chest Physicians



Thoracic Manifestations of Inflammatory Bowel Disease

Hugh Black, Mark Mendoza and Susan Murin

Chest 2007;131;524-532
DOI 10.1378/chest.06-1074

A focused literature review of respiratory abnormalities in 155 patients with known IBD.

Respiratory symptoms and diagnosed respiratory system disorders are more common among patients with IBD than generally appreciated. The spectrum of respiratory disorders occurring among patients with IBD is very broad.

Bronchiectasis is the most frequently reported form of IBD-associated lung disease.

BOOP and serositis follow in frequency

IBD patients also have a threefold risk of venous thromboembolism, and recent investigations have also revealed possible ties between IBD and other diseases involving the respiratory system, including sarcoidosis, asthma, and 1-antitrypsin deficiency.

| Site of Involvement | Cases, No. |
|--|---------------|
| Upper airway ²⁹⁻³⁹ | 15 |
| Trachea | 15 |
| Larynx/glottis | 2 |
| Large airways ^{29-31,40-53} | 67 |
| Bronchiectasis | 44 |
| Chronic bronchitis | 13 |
| Suppurative airway disease | 5 |
| Acute bronchitis | 2 |
| Small airways ^{32,46,50,54-61} | 17 |
| Bronchiolitis | 10 |
| Bronchiolitis obliterans | 6 |
| Diffuse panbronchiolitis | 1 |
| Parenchyma ^{30,45,46,53,56,61-76} | 40 |
| BOOP | 21 |
| Nodules | 6 |
| Interstitial lung disease not otherwise specified | 6 |
| Pulmonary interstitial emphysema | 3 |
| Desquamative interstitial pneumonia | 1 |
| Nonspecific interstitial pneumonia | 1 |
| Fibrosing alveolitis | 1 |
| Eosinophilic pneumonitis | 1 |
| Sarcoidosis | NS |
| α 1-Antitrypsen deficiency | NS |
| Pulmonary vasculature ^{30,60,73-75,77-81} | 10 |
| Wegener granulomatosis | 3 |
| Churg-Strauss syndrome | 1 |
| Microscopic polyangiitis | 2 |
| Pulmonary vasculitis not otherwise specified | 4 |
| Serosa ^{30,59,65-67,73-75,82-87} | 22 |
| Pleural disease | 12 |
| Pericardial disease | 15 |

HRCT 1/10
C: GASTROGRAFIN
Se: 3/3
Im: 10/19
Ax: S404.0

F 3371219
Acc: 93840
2008 Feb 05
Acq Trn: 18:53:34.902058

reconMatrix=512
512 x 512
CHST


R

L

140.0 kV
145.0 mA
1.0 mm/0.0:1
Tilt: 0.0
1.5 s
Lin:DCM / Lin:DCM / Id:ID
W:1898 L:-275

P

DFOV: 28.8 x 28.8cm



HRCT 1/10
C: GASTROGRAFIN
Se: 3/3
Im: 11/19
Axc: S394.0

F 3371219
Acc: 93840
2008 Feb 05
Acq Tm: 18:53:37.807804

reconMatrix=512
512 x 512
CHST


R

L


140.0 kV
145.0 mA
1.0 mm/0.0:1
Tilt: 0.0
1.5 s
Lin:DCM / Lin:DCM / Id:ID
W:1898 L:-275

P

DFOV: 28.8 x 28.8cm



Bronchiolitis



State of the Art

Am J Respir Crit Care Med Vol 168. pp 1277-1292, 2003


Bronchiolar Disorder

Jay H. Ryu, Jeffrey L. Myers, and Stephen

Cryptogenic Constrictive Bronchiolitis A Clinicopathologic Study

MONICA KRAFT, REBECCA L. MORTENSON, THOMAS V. COLBY, LEE NEWMAN,
JAMES A. WALDRON, JR., and TALMADGE E. KING, JR.

Am Rev Respir Dis 1993; 148:1093-101.



Insult



Injury or destruction of small airway epithelium



Acute and chronic inflammatory response




Repair by proliferation of granulation tissue




Intramural and intraluminal fibrosis



Airway obliteration



Bronchiolitis



CHEST[®]


Official publication of the American College of Chest Physicians




Bronchiolitis Obliterans Syndrome : The Final Frontier for Lung Transplantation

Jamie L. Todd and Scott M Palmer


Chest 2011;140;502-508
DOI 10.1378/chest.10-2838






Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation—An Increasingly Recognized Manifestation of Chronic Graft-versus-Host Disease

Jason W. Chien,¹ Steven Duncan,² Kirsten M. Williams,³ Steven Z. Pavletic³



Bronchiolitis



**BRIEF REPORT: IDIOPATHIC DIFFUSE
HYPERPLASIA OF PULMONARY
NEUROENDOCRINE CELLS AND
AIRWAYS DISEASE**

**SAMUEL M. AGUAYO, M.D., YORK E. MILLER, M.D.,
JAMES A. WALDRON, JR., M.D., PH.D.,
ROBERT M. BOGIN, M.D.,
MARY E. SUNDAY, M.D., PH.D.,
GERALD W. STATON, JR., M.D.,
WILLIAM R. BEAM, M.D.,
AND TALMADGE E. KING, JR., M.D.**

CANCER

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease

Susan J Davies, John R Gosney, David M Hansell, Athol U Wells, Roland M du Bois, Margaret M Burke, Mary N Sheppard, Andrew G Nicholson

Thorax 2007;62:248–252. doi: 10.1136/thx.2006.063065



Pulmonary Perspective


Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia



A Systematic Overview


Adrienne A. Nassar¹, Dawn E. Jaroszewski², Richard A. Helmers³, Thomas V. Colby⁴, Bhavesh M. Patel⁵, and Farouk Mookadam⁶





¹Division of Internal Medicine, Department of Medicine; ²Division of Cardiothoracic Surgery, Department of Surgery; ³Division of Pulmonary Medicine, Department of Medicine; ⁴Department of Laboratory Medicine and Pathology; ⁵Department of Critical Care; and ⁶Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Scottsdale, Arizona













Bronchiolitis



INTERSTITIAL LUNG DISEASES



American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias

THIS JOINT STATEMENT OF THE AMERICAN THORACIC SOCIETY (ATS), AND THE EUROPEAN RESPIRATORY SOCIETY (ERS) WAS ADOPTED BY THE ATS BOARD OF DIRECTORS, JUNE 2001 AND BY THE ERS EXECUTIVE COMMITTEE, JUNE 2001

